Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares of common stock and sold 10,000 shares in open-market transactions. The options had an exercise price of $81.49 per share, while the reported sales occurred around $169.57–$170.91 per share on June 26 and June 29, 2026.
The filing shows this as an exercise-and-sell pattern, converting option value into cash rather than increasing net share ownership. After these transactions, Lippoldt directly holds 54,729 shares of Neurocrine Biosciences common stock and retains additional non-qualified stock options. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025.
NBIX proposes sale of 9,800 shares of Common Stock. The notice lists an Exercise of Stock Options on 06/29/2026 and specifies cash as the consideration method. The filing also shows 10b5-1 sales of 200 shares on 06/26/2026 as recent activity.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin reported an exercise-and-sell Form 4 transaction in company common stock. On June 5, 2026, he exercised non-qualified stock options for a total of 25,000 shares of common stock at exercise prices of $79.79 and $53.64 per share. On the same date, he conducted open-market sales totaling 25,000 shares at weighted average prices ranging from about $163.81 to $167.31 per share, executed in multiple trades.
The filing notes that the dispositions were carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and company policy restricts changes to such plans after adoption. Following these transactions, Sherwin directly holds 15,860 shares of Neurocrine Biosciences common stock, and the exercised options reported here no longer remain outstanding.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported a charitable stock gift. On June 5, 2026, Onyia transferred 2,441 shares of common stock as a bona fide gift, with no price reported and no value received. Following the gift, Onyia directly holds 23,405 common shares. The filing notes this was not a market transaction, so it does not reflect open-market buying or selling activity.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 1,250 shares of common stock in an open-market transaction on June 4, 2026 at a weighted average price of about $168.06 per share. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, and Norwalk now directly holds 2,838 shares.
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported a mix of option exercise and share sales in company common stock. On June 2, 2026, she exercised 24,965 non-qualified stock options at an exercise price of $81.49 per share, converting them into common shares. The filing shows her holding 59,311 common shares directly after this exercise.
That same day, she executed a series of open-market sales totaling 36,937 common shares at weighted average prices ranging from the mid‑$154 to high‑$158 area, with specific ranges from $154.20 to $158.91. A footnote states these dispositions were carried out by a broker under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 3, 2026. The filing also notes that 20,334 of the reported shares are held by the Cooke Family Trust of 2004, over which Cooke has voting and investment power.
Neurocrine Biosciences’ Chief Medical Officer Sanjay Keswani reported routine equity-compensation activity. On June 2 2026, 3,212 restricted stock units (RSUs) vested, each converting into one share of common stock. To cover tax withholding on this vesting, 1,733 shares were withheld by the company at $154.84 per share; no shares were sold on the market.
The RSU grant, originally awarded on June 2 2025, vests over four years: 3,212 shares vested on June 2 2026 and further tranches of 3,212, 3,211 and 3,211 shares are scheduled to vest annually through June 2 2029, subject to award conditions.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised stock options and sold shares on June 1, 2026. He exercised options for 11,000 shares of common stock at an exercise price of $84.74 per share and sold 11,000 shares in an open-market transaction at a weighted average price of $160.2464 per share, with sale prices ranging from $160.00 to $160.66. After these transactions, he directly holds 25,846 shares of common stock and 13,268 non-qualified stock options. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, which the company’s policy does not allow him to amend after adoption.